Engflag

Algimide

Quick links to important sections

Algimide

Algimide_PL

Method of action: Analgesic, Antitussive Opioid, Opioid

Treatment option: Period Pain, Pain, Headache, Toothache, Migraine, Neuralgia

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Algimide

Property Description
Active Ingredients Acetaminophen, Codeine
Form Oral (Tablet, Capsule, Solution)
Pharmacological Class Narcotic Analgesic Combination
General Purpose Relief of mild to moderate pain
Origin Synthetic (Acetaminophen) & Semisynthetic (Codeine)

What is the Pharmacological Class of Algimide?

Algimide is a combination medicine classified as a narcotic analgesic combination, used for pain relief that is typically characterized as mild to moderate. This designation indicates that the product contains two different active compounds, an opioid and a non-opioid, working in tandem to enhance efficacy. The acetaminophen and codeine combination is recognized as a component for managing pain at the second step of the analgesic ladder, used when non-opioids alone are insufficient. Clinically recognized for this specific use, the combination’s efficacy is a documented aspect of its pharmacological profile.

What is Algimide Made Of? (Composition and Origin)

Algimide is composed of the active ingredients acetaminophen and codeine, representing both a synthetic compound and a semisynthetic derivative. Acetaminophen (paracetamol) functions as the non-opioid analgesic and antipyretic component, which is entirely synthetic in origin. Conversely, codeine is classified as an opioid analgesic and is a semisynthetic opioid alkaloid derived from the opium poppy. This dual formulation is common, with many comparable products on the market. Codeine is a prodrug that must be metabolized into morphine, its most active form, to achieve its central pain-relieving effect. The chemical composition is standardized, detailing the components involved, such as acetaminophen and codeine phosphate.

What Dosage Forms is Algimide Available In?

Algimide is commonly manufactured as an oral dosage form, designed to be taken by mouth. Available preparations include solid forms, such as tablets and capsules, alongside liquid presentations like oral solutions or suspensions. All forms are designed for oral administration, utilizing either solid excipients or an aqueous/hydroalcoholic base, depending on the dosage form. The availability of multiple dosage forms ensures appropriate delivery for different patient needs.

Regulatory References

  1. WHO Analgesic Ladder (via NIH Bookshelf)
  2. Acetaminophen and Codeine Phosphate Oral Solution (DailyMed)

What side effects are possible with Algimide?

Possible Side Effects and Safety Information for Algimide

This information describes the documented safety profile of Algimide, as established by authoritative governmental regulatory agencies like the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA).

Adverse Reaction Scope

The adverse reactions associated with Algimide are formally classified by frequency of occurrence and grouped by the System-Organ-Class (SOC) they affect. These classifications provide the official regulatory context for understanding the drug's risks.

Classification Example Categories
Frequency Bands Very Common (ge 1/10), Common, Uncommon, Rare
System-Organ-Classes Gastrointestinal Disorders, Nervous System Disorders, Skin and Subcutaneous Tissue Disorders

Serious Adverse Reactions (SARs): Regulatory documents specify certain adverse events that are considered life-threatening or require intervention to prevent permanent impairment. These reactions are highlighted as they represent the most critical safety concerns observed in clinical trials and post-market surveillance.

Population-Specific Safety Considerations: The official label includes specific restrictions for certain patient populations. For example, use may be limited or require close monitoring in patients with pre-existing severe renal or hepatic impairment, or in specific age groups, based on data reviewed by the regulatory bodies.

Safety-Related Restrictions: Formal limitations on use are documented and include required monitoring (e.g., periodic laboratory tests for organ function) or situations where the medicine is contraindicated (must not be used) due to an unacceptable risk.

Regulatory Safety Summary

The structured safety information formally documents the full spectrum of known risks, from common, expected events to rare, serious ones. This structure is intended to guide healthcare providers and inform patients of the official, scientifically evaluated risk profile of the medicine.

Overdose and Emergency Response

Overdose and when to seek help

Algimide overdose is a medical emergency classified as potentially life-threatening due to the combined toxicity of its two active components.

Documented overdose presentations involve symptoms of acute CNS and respiratory depression from the opioid component, including slowed or shallow breathing, extreme somnolence progressing to coma, and pinpoint pupils (miosis). Acetaminophen toxicity initially presents with non-specific signs such as nausea, vomiting, diaphoresis, and upper abdominal pain.

Severe outcomes are characterized by the risk of respiratory arrest and fatal hepatic necrosis (Acute Liver Failure). The severity is associated with ingestion that exceeds the maximum daily dose or the concurrent use of multiple acetaminophen-containing products.

Regulatory instructions mandate that individuals seek immediate medical attention and contact emergency services or a Poison Control Center immediately, even if initial symptoms are absent. Overdose management requires symptomatic and supportive measures along with the administration of specific antidotes: Naloxone to reverse opioid effects and N-acetylcysteine (NAC) to mitigate acetaminophen hepatotoxicity. Continuous monitoring of vital signs and plasma drug levels is required for acute care.

Specific risk factors for severe outcomes are documented in patients with pre-existing hepatic impairment or those classified as CYP2D6 ultra-rapid metabolizers.

Therapeutic Uses of Algimide

This medication is commonly used to relieve symptoms related to physical discomfort, and is considered relevant for easing symptoms related to systemic imbalance, such as fever.

Algimide may be applied across domains where additional symptomatic support is needed, primarily for managing mild to moderate pain. Conditions presenting with acute episodes where this medication is used include pain following acute dental procedures, discomfort after minor surgeries, and musculoskeletal injuries. The primary therapeutic benefit provides support that helps ease the symptom intensity, assisting with maintaining functional stability during difficult episodes.

“It is relevant when supportive symptom management is appropriate, especially when pain symptoms interfere with daily functioning.”

This combination is helpful in situations where multiple symptoms occur together, specifically addressing physical discomfort that co-occurs with fever. This dual action supports patients during episodes of heightened discomfort, helping to ease the overall symptom load when both manifestations are present.

Quick Fact: Addressing Symptoms of Moderate Discomfort
Symptom Category: Pain that is mild to moderate.
Use Context: When additional symptomatic support is needed.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Eligibility Scope

Algimide is generally allowed for adult patients who do not have documented contraindications. Use is often not recommended for adolescents aged 12 to 18 who possess additional risk factors for breathing difficulties, such as obstructive sleep apnea or severe lung disease.

Populations for Whom Use is Contraindicated

Official regulatory documents explicitly prohibit the use of this medicine in several groups. This includes children younger than 12 years of age for all indications. It is also contraindicated for patients under 18 years of age for pain management following tonsillectomy or adenoidectomy. Individuals identified as CYP2D6 ultra-rapid metabolizers must not use the medicine. Additionally, use is contraindicated in breastfeeding mothers and in patients with severe respiratory depression or severe hepatic insufficiency.

Condition-Specific Eligibility Rules

Severe impairment of major organs can affect eligibility. Use is contraindicated in patients with severe hepatic impairment and severe respiratory depression. Patients with severe renal impairment or who are older adults (geriatric) are categorized as requiring caution or special consideration due to increased sensitivity or reduced clearance.

Connection to the Overall Eligibility Profile

The official eligibility profile strictly defines absolute prohibitions and conditional restrictions, primarily driven by the codeine component. This structure ensures that patient groups with heightened risks, particularly related to age, metabolism, and existing comorbidities, are excluded or closely monitored according to governmental labeling.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Algimide is associated with a moderate potential for pharmacokinetic drug-drug interactions, primarily due to its metabolism by and influence on the cytochrome P450 (CYP) enzyme system. This system, particularly the CYP3A4 and CYP2C9 enzymes, is critical for metabolizing a large number of other medications, and interactions can lead to clinically significant changes in drug exposure.

Documented Pharmacokinetic Interactions

Mechanism Interacting Product Class/Agent Interaction Classification
CYP3A4 Induction Strong CYP3A4 Inducers (e.g., rifampin, phenytoin, carbamazepine) Use-With-Caution (Potential for reduced Algimide efficacy)
CYP3A4/2C9 Inhibition Strong CYP3A4/2C9 Inhibitors (e.g., fluconazole, ketoconazole, protease inhibitors) Use-With-Caution (Potential for increased Algimide exposure and side effects)

Co-administration with strong CYP3A4 inducers may lead to accelerated metabolism of Algimide, resulting in lower blood concentrations and a potential loss of therapeutic effect. Conversely, combining Algimide with strong inhibitors of the primary metabolizing enzymes may decrease its clearance, causing the drug to accumulate and increasing the risk of dose-related adverse effects.

Timing-Based Conditions: No mandatory timing-based spacing requirements (e.g., 2-hour separation) are documented; however, dose adjustments and therapeutic monitoring are typically required when co-administering with potent CYP inhibitors or inducers. Due to its potential to inhibit P-glycoprotein (P-gp), Algimide may also increase the absorption and systemic exposure of orally administered P-gp substrate medicines like digoxin.

Mechanism of Action

The mechanism of Algimide relies on two complementary central nervous system (CNS) actions. The opioid component acts as a prodrug, undergoing O-demethylation by the CYP2D6 enzyme to form the active metabolite, Morphine. This functions as an agonist at the mu-Opioid Receptors ( MOR), initiating a G-protein coupled cascade that inhibits neuronal activity. This action alters supraspinal nociceptive processing by inhibiting ascending signals and modifying central signal registration. The non-opioid component acts centrally via two distinct pathways. Its active metabolite, AM404, modulates the endocannabinoid system and activates the TRPV1 channel, which modulates nociceptive signal transmission in the spinal cord. Concurrently, it causes the inhibition of prostaglandin E2 ( PGE2) synthesis exclusively within the hypothalamus. This central PGE2 reduction promotes peripheral vasodilation and diaphoresis, leading to a resetting of the hypothalamic temperature set point. The combined effect utilizes a supra-additive mechanism, though its efficacy is constrained by the rate of CYP2D6 conversion, as Poor Metabolizers fail to adequately stimulate MORs.

Dosage and Administration Information

Algimide is a combination medicine indicated for oral administration, available in solid dosage forms like tablets and capsules, as well as an oral solution. The standard adult regimen for use involves taking one to two tablets or capsules every four hours as required for symptoms. When using the liquid form, a dose of 15 milliliters (mL) is commonly used, also subject to the four-hour interval.

It is important to adhere to the frequency pattern, as usage instructions restrict the total daily intake of the acetaminophen component to not exceed 4,000 milligrams (4 grams) within any 24-hour period. This dosing limit defines the maximum use of the medicine, regardless of the formulation used. Administration of Algimide is typically for the short-term management of acute episodes. The medicine may be taken with or without food, though liquid preparations require measurement using a calibrated dosing device to ensure precision.

Dosage guidelines for specific populations include important restrictions: the medicine is contraindicated for use in children younger than 12 years of age and in adolescents younger than 18 years following certain surgical procedures like tonsillectomy or adenoidectomy. Furthermore, caution is advised, and dose adjustment may be necessary for patients with severe hepatic or renal impairment, reflecting considerations for use in specialized patient groups.

Recent Clinical Evidence

Algimide: Recent Clinical Evidence

The following outline describes the types of research and general findings related to the components of this combination therapy. These summaries strictly report what studies evaluated, not to provide advice or therapeutic guarantees.

Dual-Action Component Research

Studies have focused on the components of the treatment to understand their actions. Research examined whether the treatment was associated with changes in mood and motivation.

Research on Major Depressive Disorder (MDD)

Symptom Measures

Research has explored the relationship between the drug and symptoms associated with MDD. Studies reported findings examining symptoms of depression, including anhedonia and low energy.

Discontinuation Effects

Research has also examined the effects of discontinuation, and findings suggest that abrupt cessation may be associated with certain effects.

Research on Parameters Related to Body Weight

Appetite and Metabolism Measures

Findings suggested an association with parameters related to body weight. Research examined whether the treatment was associated with changes in appetite and metabolism. Comparative research has not yet established whether the combination provides any difference in outcome compared to other treatments.

Research on Impulsive and Compulsive Disorders

Behavioral Measures

Research explored the relationship between the drug and measures of emotional regulation and impulsive behaviors.

Research Participant Demographics

Studies have reported findings related to the presence of seizures in research participants. Research is evaluating its role in individuals experiencing refractory depression, but evidence remains limited.

How should Algimide be stored and disposed of?

How to Store and Dispose of Algimide? (Official Guidance)

Algimide must be stored strictly according to the official regulatory guidelines to maintain its stability and effectiveness.

Requirement Official Instruction
Temperature Store at controlled room temperature (e.g., 20°C to 25°C). Do not expose the product to temperatures above 30°C.
Protection Keep out of the reach of children. Store in the original, tightly closed container and protect from light and moisture. Do not freeze.
Stability Do not use Algimide after the expiration date printed on the packaging. Liquid formulations may require discarding any unused portion 30 days after first opening.
Disposal Do not flush unused or expired Algimide down the toilet or pour it down a drain. Dispose of the medicine at a designated drug take-back location or authorized collection site to ensure compliance with environmental and pharmaceutical waste regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagColombia

Equivalent of Algimide found in:

A-Z Index: